SCHEMBL25029462

SCHEMBL25029462

COC(=O)c1cc2c(Oc3c(F)cc(N)c(Cl)c3F)ccnc2cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 8/20 0.51
▸ PDGFRA P16234 8/20 0.47
▸ PDGFRB P09619 2/20 0.47
▸ MERTK Q12866 4/20 0.44
▸ MET P08581 2/20 0.44
▸ KDR P35968 10/20 0.43
▸ AURKB Q96GD4 2/20 0.43
▸ AURKA O14965 1/20 0.43
▸ TEK Q02763 1/20 0.43
▸ KIT P10721 2/20 0.42
▸ FGFR2 P21802 2/20 0.42
▸ RIPK2 O43353 1/20 0.42
▸ ERN1 O75460 1/20 0.42
▸ STK10 O94804 1/20 0.42
▸ MAP3K6 O95382 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ RET P07949 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ BCR P11274 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25028717 0.91 PDGFRB (0.54) AXLPDGFRAPDGFRBMETKDR
SCHEMBL25166708 0.91 AXL (0.53) AXLPDGFRAPDGFRBMERTKMET
SCHEMBL25028718 0.83 PDGFRB (0.54) AXLPDGFRAPDGFRBMERTKMET
SCHEMBL25028733 0.83 KDR (0.52) AXLPDGFRAPDGFRBMETKDR
SCHEMBL25028720 0.83 KDR (0.52) AXLPDGFRAPDGFRBMETKDR
SCHEMBL25028726 0.82 KDR (0.55) AXLPDGFRAPDGFRBMETKDR
SCHEMBL25028719 0.82 PDGFRB (0.53) AXLPDGFRAPDGFRBMERTKMET
SCHEMBL25028729 0.82 KDR (0.52) AXLPDGFRAPDGFRBMERTKMET
SCHEMBL25028724 0.81 KDR (0.54) AXLPDGFRAPDGFRBMETKDR
SCHEMBL25038926 0.81 PDGFRA (0.58) AXLPDGFRAPDGFRBMETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 — — US disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 — — US disclosed
US-20230124784-A1 MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES SHANGHAI AB PHARMATECH LTD. (CN) 2023-04-20 — — US disclosed
WO-2023016543-A1 UREA MULTI-TARGET TYROSINE KINASE INHIBITOR AND MULTIPLE MEDICAL APPLICATIONS THEREOF 上海爱博医药科技有限公司 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses ABL1, ERBB2, RET AXL 134/4885PDGFRA 442/4885PDGFRB 359/4885
US-20230124784-A1 MULTI-TARGETED TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL USES ABL1, ERBB2, RET AXL 134/4885PDGFRA 442/4885PDGFRB 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback